elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q49958882-05D0E88D-3AB4-4835-8CBA-DBC157EBACC9
Q49958882-05D0E88D-3AB4-4835-8CBA-DBC157EBACC9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49958882-05D0E88D-3AB4-4835-8CBA-DBC157EBACC9
[Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application].
P2860
Q49958882-05D0E88D-3AB4-4835-8CBA-DBC157EBACC9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49958882-05D0E88D-3AB4-4835-8CBA-DBC157EBACC9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
89e84913a19747721bc834f7324d77ed99001144
P2860
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer